Benefits
Postprandial blood sugar and insulin reduction
A human RCT of Eriomin® (200 mg/day) demonstrated significant reductions in postprandial blood glucose and insulin response after 12 weeks — with improvements in both fasting glucose and the 2-hour glucose excursion during oral glucose tolerance testing. Proposed mechanisms include alpha-glucosidase inhibition and improved insulin sensitivity. Note: the branded human trials to date come from a single research group and are manufacturer-affiliated, so independent replication remains limited.
Uric acid reduction
Eriocitrin significantly reduces serum uric acid levels through xanthine oxidase inhibition (the enzyme that produces uric acid) in laboratory and mechanistic studies. This uric-acid effect is mechanistic and has not been a primary endpoint of the branded human RCTs cited on this page, which measured glucose and metabolic markers rather than uric acid. Eriocitrin is not a substitute for prescription urate-lowering therapy and is not intended to treat or prevent gout.
Antioxidant and anti-inflammatory activity
Eriocitrin and its metabolite eriodictyol are potent free radical scavengers with ORAC values among the highest of citrus flavonoids. Clinical studies show reductions in CRP and inflammatory markers in the branded human trials; effects on oxidized LDL are mechanistic/preclinical rather than a demonstrated outcome.
Cardiovascular protection
In mechanistic and preclinical studies, eriocitrin and related citrus flavonoids may influence endothelial function, nitric oxide signaling, and platelet activity. These cardiovascular effects are mechanistic and were not measured in the branded Eriomin® human trials cited here, so any cardiovascular benefit in people remains unproven — best framed as general antioxidant and vascular support rather than a demonstrated outcome.
Mechanism of action
Alpha-glucosidase and xanthine oxidase dual inhibition
Eriocitrin inhibits intestinal alpha-glucosidase (slowing carbohydrate digestion and glucose absorption) and xanthine oxidase (the enzyme producing uric acid from purines). This dual enzyme inhibition explains why eriocitrin simultaneously reduces postprandial blood glucose and serum uric acid — two key metabolic syndrome markers — through direct enzyme interaction.
PPAR-α activation and lipid metabolism
Eriodictyol (the aglycone of eriocitrin) activates PPAR-α transcription factor, stimulating fatty acid oxidation, reducing triglyceride synthesis, and improving overall lipid metabolism. This PPAR-α agonism contributes to the lipid-lowering and insulin-sensitizing effects of eriocitrin supplementation.
NF-κB inhibition and oxidative stress reduction
Eriocitrin inhibits NF-κB activation and reduces downstream inflammatory cytokine production. The antioxidant mechanism involves both direct free radical scavenging and Nrf2 pathway activation, providing complementary anti-inflammatory and antioxidant protection in metabolic tissues.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Eriomin® (200 mg/day, lemon-derived eriocitrin extract) vs placebo in 103 pre-diabetic adults for 12 weeks. Outcomes: fasting glucose, HOMA-IR, lipid profile, inflammatory markers. (Ribeiro et al. 2019, Phytother Res — the branded pivotal prediabetes RCT)
103 pre-diabetic adults. 12-week intervention.
Eriomin® significantly reduced fasting blood glucose, postprandial glucose AUC, insulin resistance (HOMA-IR), and inflammatory markers vs placebo. Modest but clinically meaningful effect sizes. Note: published trial — adds peer-reviewed support to manufacturer claims.
The uric-acid / xanthine-oxidase effect derives from mechanistic and preclinical work; a verified human uric-acid RCT specific to eriocitrin (or Eriomin®) is lacking. The previously listed attribution (Hiramitsu 2014) is an eriocitrin fatty-liver study, and the previously linked PMID was a different bergamot/cardoon NAFLD paper.
Adults with mildly elevated uric acid.
Eriocitrin reduced serum uric acid and inhibited xanthine oxidase activity in this study. Human uric-acid RCT evidence specific to the branded Eriomin® ingredient is limited and this citation should be verified. Reductions were modest compared to allopurinol or febuxostat (pharmaceutical xanthine oxidase inhibitors) — eriocitrin should be considered adjunctive, not a substitute for medication in clinical hyperuricemia/gout.